bapineuzumab
Jump to navigation
Jump to search
Indications
- none
Contraindications
- treatment of Alzheimer's disease
Dosage
- intravenous administration
Mechanism of action
- monoclonal antibody against beta-amyloid
Clinical trials
- in 2 clinical trials, bapineuzumab failed to improve cognitive function in patients with mild to moderate Alzheimer's disease
More general terms
References
- ↑ Reuter August 7, 2012 Pfizer, J&J scrap Alzheimer's studies as drug fails http://www.reuters.com/article/2012/08/07/us-pfizer-alzheimers-idUSBRE8751F120120807
- ↑ Associated press, August 6, 2012 J&J, Pfizer to drop intravenous Alzheimer's drug http://online.wsj.com/article/APffd2cec117944e4c9c045ca6f21513f7.html
- ↑ Salloway S et al Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. N Engl J Med 2014; 370:322-333. January 23, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24450891 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1304839